Photo by bermixstudio from unsplash
Chronic lymphocytic leukemia (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib… Click to show full abstract
Chronic lymphocytic leukemia (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second generation oral inhibitor of phosphoinositide-3 kinase (PI3K), downstream of the B-cell receptor pathway, approved in the United States for relapsed CLL/SLL and FL. Duvelisib represents a highly active agent and ongoing investigations, including fixed-duration drug combinations and alternative dosing schedules, are aimed at reducing immune mediated toxicities.
Journal Title: Blood
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!